Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Fulton Bank N.A.

Fulton Bank N.A. raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,396 shares of the medical research company’s stock after purchasing an additional 91 shares during the period. Fulton Bank N.A.’s holdings in Charles River Laboratories International were worth $669,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CRL. Vanguard Group Inc. increased its holdings in shares of Charles River Laboratories International by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock worth $1,638,290,000 after buying an additional 66,161 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its stake in Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after acquiring an additional 31,359 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Charles River Laboratories International by 3.1% in the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock worth $409,985,000 after purchasing an additional 45,079 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Charles River Laboratories International by 11.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,251,618 shares of the medical research company’s stock valued at $258,559,000 after purchasing an additional 132,802 shares in the last quarter. Finally, Meritage Group LP grew its holdings in shares of Charles River Laboratories International by 2.3% during the 1st quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock worth $320,336,000 after purchasing an additional 26,892 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $186.83 on Wednesday. The firm has a market cap of $9.62 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 4.09 and a beta of 1.36. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $201.77 and its two-hundred day moving average is $217.51. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Analysts forecast that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International declared that its board has approved a share buyback program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

Several research firms recently commented on CRL. Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. UBS Group reduced their target price on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Robert W. Baird lowered their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. The Goldman Sachs Group cut their price objective on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $217.33.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).